Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
XEN-101 by Xeno Biosciences for Obesity: Likelihood of Approval
XEN-101 is under clinical development by Xeno Biosciences and currently in Phase I for Obesity. According to GlobalData, Phase I...